Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Life Sciences Industry Analysis

UpdatedJan 11, 2026
DataAggregated Company Financials
Companies22
  • 7D0.6%
  • 3M-3.7%
  • 1Y3.6%
  • YTD1.6%

Last week, the Life Sciences industry hasn't moved much but Divi's Laboratories is up 3.5% in that time. As for the the longer term, the industry is up 3.6% over the past 12 months. As for the next few years, earnings are expected to grow by 22% per annum.

Industry Valuation and Performance

Has the Indian Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 12 Jan 2026₹3.1t₹342.6b₹48.4b32.4x65x9.2x
Wed, 10 Dec 2025₹3.1t₹342.6b₹48.4b33.4x63.2x8.9x
Fri, 07 Nov 2025₹3.3t₹331.8b₹45.5b37.1x72x9.9x
Sun, 05 Oct 2025₹3.1t₹331.4b₹45.5b45.9x67.4x9.3x
Tue, 02 Sep 2025₹3.2t₹331.4b₹45.5b41.1x69.3x9.5x
Thu, 31 Jul 2025₹3.3t₹320.3b₹41.8b54.3x80x10.5x
Sat, 28 Jun 2025₹2.9t₹300.7b₹37.4b45.2x77.3x9.6x
Mon, 26 May 2025₹2.8t₹299.2b₹35.1b51.6x78.9x9.3x
Wed, 23 Apr 2025₹2.6t₹287.4b₹30.8b48.8x84.6x9x
Fri, 21 Mar 2025₹2.6t₹287.4b₹30.8b49.5x83.6x8.9x
Sun, 16 Feb 2025₹2.5t₹287.5b₹30.8b50.4x82.3x8.8x
Tue, 14 Jan 2025₹2.5t₹269.1b₹30.1b48.3x81.5x9.1x
Thu, 12 Dec 2024₹2.4t₹254.2b₹28.8b51.8x83.4x9.5x
Sat, 09 Nov 2024₹2.4t₹248.7b₹26.1b48.7x93.1x9.8x
Mon, 07 Oct 2024₹2.3t₹247.6b₹26.3b50x86x9.1x
Wed, 04 Sep 2024₹2.1t₹247.6b₹26.3b47.2x81.8x8.7x
Fri, 02 Aug 2024₹1.9t₹201.7b₹23.8b39.2x81.9x9.6x
Sun, 30 Jun 2024₹1.8t₹198.0b₹23.7b33.8x74.5x8.9x
Tue, 28 May 2024₹1.6t₹193.7b₹21.6b34.3x76.1x8.5x
Thu, 25 Apr 2024₹1.4t₹168.5b₹18.6b30x76.9x8.5x
Sat, 23 Mar 2024₹1.3t₹168.5b₹18.6b28.8x71.1x7.8x
Mon, 19 Feb 2024₹1.4t₹168.5b₹18.6b31.1x77.1x8.5x
Wed, 17 Jan 2024₹1.4t₹165.1b₹18.8b32.9x76.6x8.7x
Fri, 15 Dec 2023₹1.3t₹155.9b₹18.1b22x74.6x8.6x
Sun, 12 Nov 2023₹1.3t₹156.4b₹18.1b21.4x72x8.4x
Tue, 10 Oct 2023₹1.4t₹154.7b₹19.7b25x70.4x9x
Thu, 07 Sep 2023₹1.4t₹154.7b₹19.7b26.4x71.8x9.1x
Sat, 05 Aug 2023₹1.4t₹158.1b₹23.2b30.1x60.7x8.9x
Mon, 03 Jul 2023₹1.3t₹157.2b₹23.0b29.2x58.3x8.5x
Wed, 31 May 2023₹1.3t₹157.7b₹22.6b37.7x56.8x8.1x
Fri, 28 Apr 2023₹1.2t₹162.6b₹28.7b33.1x41.8x7.4x
Sun, 26 Mar 2023₹1.0t₹159.5b₹28.4b31.1x37x6.6x
Tue, 21 Feb 2023₹1.1t₹159.5b₹28.4b32.1x37.8x6.7x
Thu, 19 Jan 2023₹1.2t₹164.9b₹34.5b30.1x35.6x7.4x
Price to Earnings Ratio

35.6x


Total Market Cap: ₹1.2tTotal Earnings: ₹34.5bTotal Revenue: ₹164.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Life Sciences Industry Price to Earnings3Y Average 70.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Indian Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 65.0x which is lower than its 3-year average PE of 70.6x.
  • The industry is trading close to its 3-year average PS ratio of 8.8x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 12% per year over the last three years.
  • Revenues for these companies have grown 28% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market-2.80%
Healthcare-0.88%
Life Sciences0.61%
Clinical Research and Equipment0.61%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DIVISLAB Divi's Laboratories₹6.62k3.5%
+₹59.5b		14.6%PE70.7x
DCAL Dishman Carbogen Amcis₹257.981.3%
+₹501.7m		-3.1%PE29.7x
SAILIFE Sai Life Sciences₹923.300.2%
+₹338.0m		28.3%PE68.1x
538837 Jeevan Scientific Technology₹69.757.3%
+₹75.2m		40.8%PS2.5x
539267 Samsrita Labs₹19.562.6%
+₹11.1m		-9.3%PB2.9x

Latest News

DIVISLAB
₹6,616.50
Divi's Laboratories
7D
3.5%
1Y
14.6%

DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook

Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).
SAILIFE
₹923.30
Sai Life Sciences
7D
0.2%
1Y
28.3%

Here's Why We Think Sai Life Sciences (NSE:SAILIFE) Might Deserve Your Attention Today

Jan 09
Here's Why We Think Sai Life Sciences (NSE:SAILIFE) Might Deserve Your Attention Today
SYNGENE
₹626.90
Syngene International
7D
-4.8%
1Y
-27.1%
INDGN
₹509.90
Indegene
7D
-2.4%
1Y
-17.1%

INDGN: Expanded Consulting Practice And Upcoming Meetings Will Support Continued Positive Momentum

Analysts have trimmed their fair value estimate for Indegene slightly from ₹610.25 to ₹609.63. This reflects updated assumptions on discount rate, revenue growth, profit margin and future P/E that keep the overall valuation view broadly intact.
524394
₹579.20
Vimta Labs
7D
-4.9%
1Y
23.1%
DCAL
₹257.98
Dishman Carbogen Amcis
7D
1.3%
1Y
-3.1%
AKUMS
₹444.80
Akums Drugs and Pharmaceuticals
7D
-1.6%
1Y
-28.1%

AKUMS: Zambian Manufacturing Expansion Will Support Future Earnings And Margin Strength

Analysts have modestly revised their price target for Akums Drugs and Pharmaceuticals to ₹638.33 per share, reflecting slightly lower discount rate and future P/E assumptions while maintaining their outlook on revenue growth and profit margins. What's in the News The board has approved a USD 24 million (about INR 2,000 million) investment in subsidiary Akums Healthcare Zambia to establish a manufacturing facility and expand its presence in Zambia and neighboring African markets, with funding via equity and/or debt secured by MIGA insurance (Key Developments).
ONESOURCE
₹1,760.40
OneSource Specialty Pharma
7D
-2.2%
1Y
n/a

A Look At The Intrinsic Value Of OneSource Specialty Pharma Limited (NSE:ONESOURCE)

Dec 15
A Look At The Intrinsic Value Of OneSource Specialty Pharma Limited (NSE:ONESOURCE)
INNOVACAP
₹703.70
Innova Captab
7D
-3.0%
1Y
-34.9%

INNOVACAP: Stable Margins And Growth Outlook Will Drive Future Upside Potential

Analysts have maintained their price target for Innova Captab at ₹808.5 per share, noting that only minor adjustments to the discount rate and long term valuation assumptions were needed, based on stable growth and margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 (company board filing).
538837
₹69.75
Jeevan Scientific Technology
7D
7.3%
1Y
40.8%
530239
₹159.75
Suven Life Sciences
7D
-3.2%
1Y
24.3%
ANTHEM
₹629.70
Anthem Biosciences
7D
-3.8%
1Y
n/a
539267
₹19.56
Samsrita Labs
7D
2.6%
1Y
-9.3%